Pharmacotherapies for Parkinson’s disease symptoms related to cholinergic degeneration

References

• Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29:1583–1590.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8:464–474.
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev. 1966;18:925–964.
   PubMed Web of Science ®Google Scholar
• Fahn S. The history of dopamine and levodopa in the treatment of Parkinson’s disease. Mov Disord. 2008;23(Suppl 3):S497–508.
   PubMedGoogle Scholar
• Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003;4:49–60.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in lewy bodies. Nature. 1997;388:839–840.
   PubMed Web of Science ®Google Scholar
• Cooper AA, Gitler AD, Cashikar A, et al. α-synuclein blocks ER-golgi traffic and rab1 rescues neuron loss in Parkinson’s Models. Science. 2006;313:324–328.
   PubMed Web of Science ®Google Scholar
• Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007;8:519–529.
   PubMed Web of Science ®Google Scholar
• Mercado G, Valdes P, Hetz C. An ercentric view of Parkinson’s disease. Trends Mol Med. 2013;19:165–175.
   PubMed Web of Science ®Google Scholar
• Hetz C, Mollereau B. Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nat Rev Neurosci. 2014;15:233–249.
   PubMed Web of Science ®Google Scholar
• Lim SY, Fox SH, Lang AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol. 2009;66:167–172.
   PubMedGoogle Scholar
• Katzenschlager R, Sampaio C, Costa J, et al. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev. 2003;2:CD003735.
   Google Scholar
• Muller ML, Bohnen NI. Cholinergic dysfunction in Parkinson’s disease. Curr Neurol Neurosci Rep. 2013;13:377.
   PubMed Web of Science ®Google Scholar
• Picciotto Marina R, Higley Michael J, Mineur Yann S. Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron. 2012;76:116–129.
   PubMed Web of Science ®Google Scholar
• Descarries L, Gisiger V, Steriade M. Diffuse transmission by acetylcholine in the CNS. ProgNeurobiol. 1997;53:603–625.
   Google Scholar
• Descarries L, Parent M. Chapter fourteen - asynaptic and synaptic innervation by acetylcholine neurons of the central nervous system. In: Pickel V, Segal M, editors. The synapse. Boston: Academic Press; 2014. p. 447–466.
   Google Scholar
• Newman EL, Gupta K, Climer JR, et al. Cholinergic modulation of cognitive processing: insights drawn from computational models. Front Behav Neurosci. 2012;6:24.
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Mufson EJ, Wainer BH, et al. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (ch1-ch6). Neuroscience. 1983;10:1185–1201.
   PubMed Web of Science ®Google Scholar
• Jeong JH, Lee DK, Blouet C, et al. Cholinergic neurons in the dorsomedial hypothalamus regulate mouse brown adipose tissue metabolism. Mol Metab. 2015;4:483–492.
   PubMed Web of Science ®Google Scholar
• Nys M, Kesters D, Ulens C. Structural insights into cys-loop receptor function and ligand recognition. Biochem Pharmacol. 2013;86:1042–1053.
   PubMed Web of Science ®Google Scholar
• Barrantes FJ. Phylogenetic conservation of protein–lipid motifs in pentameric ligand-gated ion channels. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2015;1848:1796–1805.
   PubMed Web of Science ®Google Scholar
• Kaiser S, Wonnacott S. alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release. Mol Pharmacol. 2000;58:312–318.
   PubMed Web of Science ®Google Scholar
• Alkondon M, Pereira EFR, Barbosa CTF, et al. Neuronal nicotinic acetylcholine receptor activation modulates γ-aminobutyric acid release from CA1 neurons of rat hippocampal slices. JPharmacolExpTher. 1997;283:1396–1411.
   Web of Science ®Google Scholar
• Egea J, Buendia I, Parada E, et al. Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection. Biochem Pharmacol. 2015;97:463–472.
   PubMed Web of Science ®Google Scholar
• Lorenz R, Samnick S, Dillmann U, et al. Nicotinic alpha4beta2 acetylcholine receptors and cognitive function in Parkinson’s disease. Acta Neurol Scand. 2014;130:164–171.
   PubMed Web of Science ®Google Scholar
• Wess J. Novel insights into muscarinic acetylcholine receptor function using gene targeting technology. Trends Pharmacol Sci. 2003;24:414–420.
   PubMed Web of Science ®Google Scholar
• Wess J, Duttaroy A, Zhang W, et al. M1-M5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. Receptors Channels. 2003;9:279–290.
   PubMedGoogle Scholar
• Karlin A. Emerging structure of the nicotinic acetylcholine receptors. NatRevNeurosci. 2002;3:102–114.
   PubMed Web of Science ®Google Scholar
• Threlfell S, Cragg SJ. Dopamine signaling in dorsal versus ventral striatum: the dynamic role of cholinergic interneurons. Front Syst Neurosci. 2011;5:11.
   PubMedGoogle Scholar
• Threlfell S, Lalic T, Platt NJ, et al. Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. Neuron. 2012;75:58–64.
   PubMed Web of Science ®Google Scholar
• Zhou FM, Wilson CJ, Dani JA. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J Neurobiol. 2002;53:590–605.
   PubMedGoogle Scholar
• Wilson CJ, Chang HT, Kitai ST. Firing patterns and synaptic potentials of identified giant aspiny interneurons in the rat neostriatum. J Neurosci. 1990;10:508–519.
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res. 2011;221:564–573.
   PubMed Web of Science ®Google Scholar
• Cachope R, Cheer JF. Local control of striatal dopamine release. Front Behav Neurosci. 2014;8:188.
   PubMed Web of Science ®Google Scholar
• Gonzales KK, Smith Y. Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions. Ann N Y Acad Sci. 2015;1349:1–45.
   PubMed Web of Science ®Google Scholar
• Lim SA, Kang UJ, McGehee DS. Striatal cholinergic interneuron regulation and circuit effects. Front Synaptic Neurosci. 2014;6:22.
   PubMedGoogle Scholar
• Faust TW, Assous M, Shah F, et al. Novel fast adapting interneurons mediate cholinergic-induced fast GABAA inhibitory postsynaptic currents in striatal spiny neurons. Eur J Neurosci. 2015;42:1764–1774.
   PubMed Web of Science ®Google Scholar
• Muller ML, Bohnen NI, Kotagal V, et al. Clinical markers for identifying cholinergic deficits in Parkinson’s disease. Mov Disord. 2015;30:269–273.
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Frey KA, Studenski S, et al. Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology. 2013;81:1611–1616.
   PubMed Web of Science ®Google Scholar
• Boonstra TA, Van Der Kooij H, Munneke M, et al. Gait disorders and balance disturbances in Parkinson’s disease: clinical update and pathophysiology. Curr Opin Neurol. 2008;21:461–471.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Negre-Pages L, Damier P, et al. Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease. JAMA Neurol. 2014;71:884–890.
   PubMed Web of Science ®Google Scholar
• MacLaren DA, Santini JA, Russell AL, et al. Deficits in motor performance after pedunculopontine lesions in rats–impairment depends on demands of task. Eur J Neurosci. 2014;40:3224–3236.
   PubMed Web of Science ®Google Scholar
• Grabli D, Karachi C, Welter ML, et al. Normal and pathological gait: what we learn from Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2012;83:979–985.
   PubMed Web of Science ®Google Scholar
• Grabli D, Karachi C, Folgoas E, et al. Gait disorders in parkinsonian monkeys with pedunculopontine nucleus lesions: a tale of two systems. J Neurosci. 2013;33:11986–11993.
   PubMed Web of Science ®Google Scholar
• Wen P, Li M, Xiao H, et al. Low-frequency stimulation of the pedunculopontine nucleus affects gait and the neurotransmitter level in the ventrolateral thalamic nucleus in 6-OHDA Parkinsonian rats. Neurosci Lett. 2015;600:62–68.
   PubMed Web of Science ®Google Scholar
• Kucinski A, Sarter M. Modeling Parkinson’s disease falls associated with brainstem cholinergic systems decline. Behav Neurosci. 2015;129:96–104.
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Muller ML, Koeppe RA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. 2009;73:1670–1676.
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Frey KA, Studenski S, et al. Extra-nigral pathological conditions are common in Parkinson’s disease with freezing of gait: an in vivo positron emission tomography study. Mov Disord. 2014;29:1118–1124.
   PubMed Web of Science ®Google Scholar
• Pelosin E, Ogliastro C, Lagravinese G, et al. Attentional control of gait and falls: is cholinergic dysfunction a common substrate in the elderly and Parkinson’s Disease? Front Aging Neurosci. 2016;8:104.
   PubMed Web of Science ®Google Scholar
• Buter TC, Van Den Hout A, Matthews FE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70:1017–1022.
   PubMed Web of Science ®Google Scholar
• Hely MA, Reid WG, Adena MA, et al. The sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837–844.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:323–332.
   PubMed Web of Science ®Google Scholar
• Velseboer DC, Broeders M, Post B, et al. Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD. Neurology. 2013;80:627–633.
   PubMed Web of Science ®Google Scholar
• Halliday GM, Leverenz JB, Schneider JS, et al. The neurobiological basis of cognitive impairment in Parkinson’s disease. Mov Disord. 2014;29:634–650.
   PubMed Web of Science ®Google Scholar
• Park HE, Park IS, Oh YS, et al. Subcortical whiter matter hyperintensities within the cholinergic pathways of patients with dementia and parkinsonism. J Neurol Sci. 2015;353:44–48.
   PubMed Web of Science ®Google Scholar
• Lee JE, Cho KH, Song SK, et al. Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2014;85:7–16.
   PubMed Web of Science ®Google Scholar
• Hall H, Reyes S, Landeck N, et al. Hippocampal lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson’s disease. Brain. 2014;137:2493–2508.
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Kaufer DI, Hendrickson R, et al. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson’s disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry. 2007;78:641–643.
   PubMed Web of Science ®Google Scholar
• Shoji Y, Nishio Y, Baba T, et al. Neural substrates of cognitive subtypes in Parkinson’s disease: a 3-year longitudinal study. PLoS One. 2014;9:e110547.
   Google Scholar
• Manganelli F, Vitale C, Santangelo G, et al. Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson’s disease. Brain. 2009;132:2350–2355.
   PubMed Web of Science ®Google Scholar
• Vardy ER, Teodorczuk A, Yarnall AJ. Review of delirium in patients with Parkinson’s disease. J Neurol. 2015;262(11):2401–2410.
   PubMed Web of Science ®Google Scholar
• Crispo JA, Willis AW, Thibault DP, et al. Associations between anticholinergic burden and adverse health outcomes in Parkinson Disease. PLoS One. 2016;11:e0150621.
   PubMed Web of Science ®Google Scholar
• Van Dort CJ, Zachs DP, Kenny JD, et al. Optogenetic activation of cholinergic neurons in the PPT or LDT induces REM sleep. Proc Natl Acad Sci U S A. 2015;112:584–589.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Miyamoto M, Miyamoto T, et al. Parkinson’s disease and sleep/wake disturbances. Curr Neurol Neurosci Rep. 2015;15:8.
   PubMed Web of Science ®Google Scholar
• Nardone R, Bergmann J, Brigo F, et al. Functional evaluation of central cholinergic circuits in patients with Parkinson’s disease and REM sleep behavior disorder: a TMS study. J Neural Transm. 2013;120:413–422.
   PubMed Web of Science ®Google Scholar
• Moro E, Hamani C, Poon YY, et al. Unilateral pedunculopontine stimulation improves falls in Parkinson’s disease. Brain. 2010;133:215–224.
   Web of Science ®Google Scholar
• Ferraye MU, Debu B, Fraix V, et al. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson’s disease. Brain. 2010;133:205–214.
   PubMed Web of Science ®Google Scholar
• Chung KA, Lobb BM, Nutt JG, et al. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology. 2010;75:1263–1269.
   PubMed Web of Science ®Google Scholar
• Henderson EJ, Lord SR, Brodie MA, et al. Rivastigmine for gait stability in patients with Parkinson’s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:249–258.
   PubMed Web of Science ®Google Scholar
• Li Z, Yu Z, Zhang J, et al. Impact of rivastigmine on cognitive dysfunction and falling in parkinson’s disease patients. Eur Neurol. 2015;74:86–91.
   PubMed Web of Science ®Google Scholar
• Pagano G, Rengo G, Pasqualetti G, et al. Cholinesterase inhibitors for Parkinson’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015;86(7):767–773.
   PubMed Web of Science ®Google Scholar
• Mamikonyan E, Xie SX, Melvin E, et al. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov Disord. 2015;30:912–918.
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):S2–41.
   PubMed Web of Science ®Google Scholar
• Nosko D, Ferraye MU, Fraix V, et al. Low-frequency versus high-frequency stimulation of the pedunculopontine nucleus area in Parkinson’s disease: a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2015;86:674–679.
   PubMed Web of Science ®Google Scholar
• Morita H, Hass CJ, Moro E, et al. Pedunculopontine nucleus stimulation: where are we now and what needs to be done to move the field forward? Front Neurol. 2014;5:243.
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351:2509–2518.
   PubMed Web of Science ®Google Scholar
• Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012;27:1230–1238.
   PubMed Web of Science ®Google Scholar
• Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76:934–939.
   PubMed Web of Science ®Google Scholar
• Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;14:CD006504.
   Google Scholar
• Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):S42–80.
   PubMed Web of Science ®Google Scholar
• Possin KL, Kang GA, Guo C, et al. Rivastigmine is associated with restoration of left frontal brain activity in Parkinson’s disease. Mov Disord. 2013;28:1384–1390.
   PubMed Web of Science ®Google Scholar
• Yarnall A, Rochester L, Burn DJ. The interplay of cholinergic function, attention, and falls in Parkinson’s disease. Mov Disord. 2011;26:2496–2503.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Tohgi H, Yonezawa H, et al. The effect of trihexyphenidyl, an anticholinergic agent, on regional cerebral blood flow and oxygen metabolism in patients with Parkinson’s disease. J Neurol Sci. 1999;167:56–61.
   PubMed Web of Science ®Google Scholar
• Lenzi GL, Jones T, Reid JL, et al. Regional impairment of cerebral oxidative metabolism in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1979;42:59–62.
   PubMed Web of Science ®Google Scholar
• Hindle JV. The practical management of cognitive impairment and psychosis in the older Parkinson’s disease patient. J Neural Transm (Vienna). 2013;120:649–653.
   PubMed Web of Science ®Google Scholar
• Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin Neuropharmacol. 2002;25:107–110.
   PubMed Web of Science ®Google Scholar
• Schrag A, Sauerbier A, Chaudhuri KR. New clinical trials for nonmotor manifestations of Parkinson’s disease. Mov Disord. 2015;30:1490–1504.
   PubMed Web of Science ®Google Scholar
• Oh YS, Kim JS, Lee PH. Effect of rivastigmine on behavioral and psychiatric symptoms of Parkinson’s Disease dementia. J Mov Disord. 2015;8:98–102.
   PubMed Web of Science ®Google Scholar
• Tampi RR, Tampi DJ, Ghori AK. Acetylcholinesterase inhibitors for delirium in older adults. Am J Alzheimers Dis Other Demen. 2016;31:305–310.
   PubMed Web of Science ®Google Scholar
• Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6:85–95.
   PubMed Web of Science ®Google Scholar
• Arnulf I, Ferraye M, Fraix V, et al. Sleep induced by stimulation in the human pedunculopontine nucleus area. Ann Neurol. 2010;67:546–549.
   PubMed Web of Science ®Google Scholar
• Emre M, Ford PJ, Bilgic B, et al. Cognitive impairment and dementia in Parkinson’s disease: practical issues and management. Mov Disord. 2014;29:663–672.
   PubMed Web of Science ®Google Scholar
• Oertel W, Poewe W, Wolters E, et al. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson’s disease dementia: a retrospective analysis of a double-blind trial and an open-label extension. Drug Saf. 2008;31:79–94.
   PubMed Web of Science ®Google Scholar
• Emre M, Poewe W, De Deyn PP, et al. Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study. Clin Neuropharmacol. 2014;37:9–16.
   PubMed Web of Science ®Google Scholar
• Minett TS, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? an open label trial in dementia with lewy bodies and Parkinson’s disease with dementia. Int J Geriatr Psychiatry. 2003;18:988–993.
   PubMed Web of Science ®Google Scholar
• Fraix V, Bastin J, David O, et al. Pedunculopontine nucleus area oscillations during stance, stepping and freezing in Parkinson’s disease. PLoS One. 2013;8:e83919.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Barrantes FJ. Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson’s disease. Npj Parkinson’s Disease. 2016;2:16001–16012.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Sampaio C, Rascol O. Parkinson’s Disease and movement disorders. In: Jankovik J, Tolosa E, editors. Disease-modifying strategies in Parkinson’s Disease. Philadelphia, PA: Wolters Kluwer; 2015.
   Google Scholar
• Bohnen NI, Kaufer DI, Hendrickson R, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2005;76:315–319.
   PubMed Web of Science ®Google Scholar
• De Germay S, Montastruc JL, Rousseau V, et al. Atropinic (anticholinergic) burden in Parkinson’s Disease. Mov Disord. 2016;31:632–636.
   PubMed Web of Science ®Google Scholar
• Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson’s disease: a review. Drugs Aging. 2008;25:665–682.
   PubMed Web of Science ®Google Scholar